---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-021219"
form_type: "8-K"
ticker: "DMAC"
cik: "0001401040"
company_name: "DiaMedica Therapeutics Inc."
filed_at: "2024-06-26T23:59:59+00:00"
generated_at: "2026-06-01T01:24:35.929482+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# DiaMedica Expands DM199 into Preeclampsia with Phase 2 Trial Starting Q4 2024

## Summary
- Phase 2 open-label, single-arm, investigator-sponsored trial enrolling up to 120 preeclampsia/FGR patients; first subject Q4 2024, topline results H1 2025.
- Trial cost estimated at ~$1.5M; led by Prof. Catherine Cluver (Stellenbosch Univ.) with collaboration from Prof. Stephen Tong (Univ. Melbourne).
- DM199 did not cross the placental barrier in rat studies; prior REDUX CKD data showed SBP reduction of 12.6 mmHg (p=0.004) in patients with baseline SBP ≥140 mmHg.
- No approved therapeutics for preeclampsia in US/Europe; DM199 is a large-molecule protein (rhKLK1) that may improve placental perfusion and reduce hypoxia.
- Company to host KOL event on July 29, 2024; conference call on June 27, 2024 at 8:00 AM ET.

## SEC filing metadata
- accession: 0001437749-24-021219
- form_type: 8-K
- ticker: DMAC
- cik: 0001401040
- company_name: DiaMedica Therapeutics Inc.
- filed_at: 2024-06-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401040/000143774924021219/0001437749-24-021219-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401040/000143774924021219/dmtp20240624_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-021219
- JSON: https://secwatch.observer/filing/0001437749-24-021219.json
- Plain text: https://secwatch.observer/filing/0001437749-24-021219.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.